NCT01641575View on ClinicalTrials.gov

A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

June 30, 2013

Conditions
Solid TumorNon-small-cell Lung CancerLung Cancer
Interventions
DRUG

CO-1.01 and Cisplatin

CO-1.01 administered over 30 minutes followed by 75 mg/ml Cisplatin over 2 hours (both intravenous) on C1D1. CO-1.01 administered intravenously over 30 minutes on C1D8.

Trial Locations (4)

34232

Florida Cancer Specialists, Sarasota

37203

Tennessee Oncology, Nashville

W1T 4TJ

University College London Cancer Institute, London

G12 0YN

The Beatson West, Glasgow

Sponsors
All Listed Sponsors
lead

Clovis Oncology, Inc.

INDUSTRY